ArticleJAC-antimicrobial resistance2025
Azithromycin resistance in
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Azithromycin-resistantJAC-antimicrobial resistance · 2026Article
- Protein-centric mechanisms of typhoidalFrontiers in cellular and infection microbiology · 2026Review
- Refractory Nontyphoidal Salmonella Empyema Necessitans in a Man Living With HIV: A Case Report and Review of the Literature.Case reports in infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Azithromycin susceptibility testing using disc diffusion (DD) and Etests has shown discrepancies with the broth microdilution (BMD) method. In this study, we assessed the association between azithromycin MIC distribution and disc inhibition zone size in Methods: Non-duplicate Results: In DD testing, false-resistance/major error was noted in 1.9% of isolates. Time-kill assay revealed slow bacteriostatic activity of azithromycin against Conclusions: The findings of the present study advocate for careful interpretation of susceptibility results and support the continued use of azithromycin in uncomplicated cases and the recommendation of combination therapy to prevent relapses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.